Stability of compounded thioguanine oral suspensions

American Journal of Health-System Pharmacy

Volumn 68, Issue 10, 2011, Pages 900-908

  Aliabadi, Hamidreza Montazeri ^a   Romanick, Marcel ^b   Somayaji, Vishwa ^a   Mahdipoor, Parvin ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b STOLLERY CHILDREN S HOSPITAL   (Canada)

Author keywords

Antineoplastic agents; Antioxidants; Ascorbic acid; Chromatography, liquid; Compounding; Concentration; Excipients; Hydrogen ion concentration; Methylcellulose; Spectrometry, mass; Stability; Storage; Suspensions; Thioguanine; Vehicles

Indexed keywords

ASCORBIC ACID; GUANINE; TIOGUANINE;

ARTICLE; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; ROOM TEMPERATURE; SHELF LIFE; SUSPENSION; SYRUP; TABLET; VALIDATION PROCESS;

EID: 79957639144     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100163     Document Type: Article

References (29)

1. Duley JA, Florin TH. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit. 2005; 27:647-54. (Pubitemid 41437645)
2. Elgemeie GH. Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites. Curr Pharm Des. 2003; 9:2627-42.
3. Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1993; 15:80-6. (Pubitemid 23061714)
4. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008; 64:753-67.
5. Sherer DW, Lebwohl MG. 6-Thioguanine in the treatment of psoriasis: a case report and literature review. J Cutan Med Surg. 2002; 6:546-50. (Pubitemid 36091500)
6. Estlin EJ. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine. Cancer Treat Rev. 2001; 27:351-63. (Pubitemid 34413979)
7. De Boer NK, Reinisch W, Teml A et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion. 2006; 73:25-31. (Pubitemid 43800658)
8. Yen Y, Grill SP, Dutschman GE et al. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res. 1994; 54:3686-91. (Pubitemid 24241179)
9. Thomas CW, Myhre GM, Tschumper R et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005; 312:537-45. (Pubitemid 40189550)
10. USP DI - Volume I: drug information for the health care professional. 26th ed. Greenwood Village, CO: Thomson Micromedex; 2009:2023.
11. Canadian Pharmaceutical Association. Compendium of pharmaceuticals and specialities (CPS). Toronto: Canadian Pharmaceutical Association; 2010:1249.
12. The United States Pharmacopeia, 32nd rev., and The national formulary, 27th ed. Rockville, MD: United States Pharmacopeial Convention; 2009:1348.
13. Sweetman S. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press; 2009:567-8.
14. The United States pharmacopeia, 32nd rev., and The national formulary, 27th ed. Rockville, MD: United States Pharmacopeial Convention; 2009:3391.
15. Ibid. pp 3725-6.
16. Gu C, Wang Y. In vitro replication and thermodynamic studies of methylation and oxidation modifications of 6-thioguanine. Nucleic Acids Res. 2007; 35:3693-704. (Pubitemid 47248463)
17. Rubin YV. Physical properties of anticancer drug 6-thioguanine. Proceedings of XVI International Conference on Spectroscopy of Molecules and Crystals. Bellingham, WA: SPIE; 2004:346-57.
18. Jin WJ, Zho RH, Shang XH et al. Effect of pH and heavy atom on solid-substrate room temperature phosphorescence of purine derivatives. Spectrochim Acta A Mol Biomol Spectrosc. 1997; 53A:1735-42. (Pubitemid 127400040)
19. Kraske PJ, Brajter-Toth A. Electrochemical oxidation of 6-thioguanine. J Electroanal Chem. 1986; 207:101-16.
20. Dressman JB, Poust RI. Stability of allopurinol and of five antineoplastics in suspension. Am J Hosp Pharm. 1983; 40:616-8. (Pubitemid 13114734)
21. Aliabadi HM, Romanick M, Desai S et al. Effect of buffer and antioxidant on stability of a mercaptopurine suspension. Am J Health-Syst Pharm. 2008; 65:441-7. (Pubitemid 351358346)
22. Zakrzewski R. Development and validation of a reversed-phase HPLC method with post-column iodine-azide reaction for the determination of thioguanine. J Anal Chem. 2009; 64:1235-41.
23. Zakrzewski R. Application of the iodine-azide postcolumn reaction in RP-HPLC for the determination of thioguanine in urine. J Separation Sci. 2008. 31:2199-205.
24. Stefan C, Walsh W, Banka T et al. Improved HPLC methodology for monitoring thiopurine metabolites in patients on thiopurine therapy. Clin Biochem. 2004; 37:764-71. (Pubitemid 39141117)
25. Erb N, Haverland U, Harms DO et al. High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary blood. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 796:87-94. (Pubitemid 38352712)
26. Dooley T, Maddocks JL. Assay of 6-thioguanine in human plasma. Br J Clin Pharmacol. 1980; 9:77-82. (Pubitemid 10176900)
27. Binkhathlan Z, Somayaji V, Brocks DR et al. Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 869:31-7.
28. Thompson JE. A practical guide to contemporary pharmacy practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2009:218-9.
29. Kibbe AH. Handbook of pharmaceutical excipients. 3rd ed. Washington, DC: American Pharmaceutical Association and Pharmaceutical Press; 2000.